NASDAQ:ZEAL

Zealand Pharma A/S - ZEAL Stock Forecast, Price & News

$17.38

+0.84 (+5.08%)

(As of 09/28/2022 12:00 AM ET)

Add

Compare

Today's Range: $16.75
▼
$17.39
50-Day Range: $16.20
▼
$20.25
52-Week Range: $9.93
▼
$32.94

Volume: 1,768 shs
Average Volume: 4,984 shs
Market Capitalization: $808.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Zealand Pharma A/S (NASDAQ:ZEAL) Stock

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZEAL Stock News Headlines

September 22, 2022 | msn.com

New Zealand sees greatest jump in adult wealth in world

September 21, 2022 | finance.yahoo.com

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

September 21, 2022 | americanbankingnews.com

Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Down to $18.15

September 15, 2022 | investing.com

Zealand Pharma A/S ADR (ZEAL)

September 7, 2022 | finance.yahoo.com

Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

September 7, 2022 | finance.yahoo.com

Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

August 11, 2022 | seekingalpha.com

Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | finance.yahoo.com

Zealand Pharma Announces Financial Results for the First Half of 2022

August 8, 2022 | finance.yahoo.com

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market

July 21, 2022 | finance.yahoo.com

Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?

July 11, 2022 | msn.com

Pristine Biologicals inaugurates New Sterile Filtered Serum manufacturing facility in New Zealand’s Dargaville

July 11, 2022 | benzinga.com

MediPharm Labs Enters Into $4.68M Purchase Agreement For The Sale Of Australian Facility

July 5, 2022 | msn.com

New Zealand’s medicines budget to boost R&D-based drugmakers

June 3, 2022 | finance.yahoo.com

Zealand Pharma to Participate in Upcoming Investor Conferences

June 2, 2022 | seekingalpha.com

Dr. David Kendall named Zealand Pharma CMO

June 2, 2022 | finance.yahoo.com

Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer

May 31, 2022 | finance.yahoo.com

Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide

May 25, 2022 | finance.yahoo.com

Zealand Pharma launches long-term incentive program for Zealand’s Corporate Management and employees for 2022

May 19, 2022 | investing.com

"We Think There is a Good Chance of Broad-label Approval" - Needham & Company Bullish on Zealand Pharma Following Phase 3 Data

May 19, 2022 | marketwatch.com

Zealand Pharma Shares Rise 16% After Trial Results for Dasiglucagon

May 19, 2022 | markets.businessinsider.com

Why Zealand Pharma Shares Are Rising

May 19, 2022 | msn.com

Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher

May 19, 2022 | seekingalpha.com

Zealand Pharma stock soars 17% as dasiglucagon meets main goal in congenital hyperinsulinism study in infants

May 19, 2022 | finance.yahoo.com

Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)

May 19, 2022 | finance.yahoo.com

Zealand Pharma to seek FDA approval of its treatment for rare genetic disorder in babies

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZEAL Company Calendar

Last Earnings: 8/11/2022
Today: 9/28/2022
Next Earnings (Estimated): 11/10/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ZEAL
CUSIP: N/A
CIK: 1674988
Web: www.zealandpharma.com
Phone: (458) 877-3600
Fax: 45-8877-3898
Employees: 355
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-161,990,000.00
Net Margins: -565.44%
Pretax Margin: -364.34%
Return on Equity: -111.04%
Return on Assets: -56.54%

Debt

Debt-to-Equity Ratio: 0.93
Current Ratio: 4.79
Quick Ratio: 4.78

Sales & Book Value

Annual Sales: $46.54 million
Price / Sales: 17.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.38 per share
Price / Book: 5.14

Miscellaneous

Outstanding Shares: 46,538,000
Free Float: 45,514,000
Market Cap: $808.83 million
Optionable: Not Optionable
Beta: 1.45

Key Executives

Mr. Adam Sinding Steensberg M.D. (Age 48)
Pres & CEO
Comp: $692.6k

Mr. Matthew Donald Dallas (Age 47)
Sr. VP & CFO
Comp: $557.88k

Mr. Ivan Mourits Moller (Age 50)
Chief Operating Officer

Lani Pollworth Morvan
Investor Relations & Communications Officer

Mr. Mads Kronborg
Head of Investor Relations & Communication

Mr. Ravinder Chahil
Sr. VP & Gen. Counsel

Ms. Christina Sonnenborg Bredal (Age 37)
Sr. VP and Global Head of People & Organization

Ms. Hanne Heidenheim Bak (Age 69)
Sr. Project Director, R&D Operations Mang. and Employee Representative Director

Dr. Jens Damsgaard Mikkelsen M.D.
Head of Molecular Pharmacology

Dr. Danilo Verge
Head of Global Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

Goldman Sachs Group Inc.
Bought 500,916 shares on 8/18/2022
Ownership: 1.077%

View All Insider Transactions
View All Institutional Transactions

ZEAL Stock - Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZEAL shares.
View ZEAL analyst ratings or view top-rated stocks.
How have ZEAL shares performed in 2022?: Zealand Pharma A/S's stock was trading at $21.34 at the beginning of the year. Since then, ZEAL shares have decreased by 18.6% and is now trading at $17.38.
View the best growth stocks for 2022 here.
When is Zealand Pharma A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our ZEAL earnings forecast.
How were Zealand Pharma A/S's earnings last quarter?: Zealand Pharma A/S (NASDAQ:ZEAL) issued its earnings results on Thursday, August, 11th. The company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.53) by $0.13. The company had revenue of $4.06 million for the quarter, compared to the consensus estimate of $2.55 million. Zealand Pharma A/S had a negative net margin of 565.44% and a negative trailing twelve-month return on equity of 111.04%.
What other stocks do shareholders of Zealand Pharma A/S own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Protalix BioTherapeutics (PLX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).
When did Zealand Pharma A/S IPO?: (ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?: Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."
Who are Zealand Pharma A/S's major shareholders?: Zealand Pharma A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (1.08%).
How do I buy shares of Zealand Pharma A/S?: Shares of ZEAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Zealand Pharma A/S's stock price today?: One share of ZEAL stock can currently be purchased for approximately $17.38.
How much money does Zealand Pharma A/S make?: Zealand Pharma A/S (NASDAQ:ZEAL) has a market capitalization of $808.83 million and generates $46.54 million in revenue each year. The company earns $-161,990,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis.
How many employees does Zealand Pharma A/S have?: The company employs 355 workers across the globe.
How can I contact Zealand Pharma A/S?: Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The official website for the company is www.zealandpharma.com. The company can be reached via phone at (458) 877-3600, via email at investors@zealandpharma.com, or via fax at 45-8877-3898.

This page (NASDAQ:ZEAL) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial